Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals reported a strong first quarter with total revenue of $106.5 million, up 159% year-over-year, driven primarily by a 97% surge in LINZESS U.S. net sales to $272.5 million. The company swung to a GAAP net income of $40.8 million, or $0.24 per share, compared to a net loss in the prior year, and maintained its full-year 2026 financial guidance.
Key figures
- Eps
- 0.24
- Revenue
- $106.5 million
- Guidance
- FY26 Total Revenue $450M-$475M; Adjusted EBITDA >$300M; U.S. LINZESS Net Sales $1.125B-$1.175B
- Revenue Yoy
- 159%
- Adjusted ebitda
- $76.7 million
- Cash and equivalents
- $220.5 million
- Linzess us net sales
- $272.5 million
- Linzess net sales yoy
- 97%
- Revolving credit facility
- $385.0 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.